Table 4 Cannabinoid hyperemesis syndrome study treatment
Study name | Study type and design | Treatment/intervention | Level of evidence* | Conclusion |
|---|---|---|---|---|
2021 Pourmand A [28]. | Retrospective—systematic review and meta-analysis | - Topical capsaicin 3–4 times a day | 2a | - Low adverse effects - Meantime to response 325 min (5.41 h) and mean time to discharge 379 min (6.31 h) |
2020 Ruberto J [25]. | Randomized, controlled trial | - Haloperidol IV 0.05–0.1 mg/kg vs ondansetron IV 8mg | 1b | - Haloperidol is superior to ondansetron for reducing abdominal pain, nausea/vomiting at 2 h after treatment - Discharge time is also shorter with haloperidol than ondansetron (3.1 h vs 5.6 h) - Four return visits with haloperidol treatment vs 6 with ondansetron |
2019 McConachie M [29]. | Retrospective—systematic review | - Topical capsaicin 3–4 times a day | 2a | - In 2019, studies are of low methodological quality to assess capsaicin efficacy in CHS but the favorable benefit-risk balance makes it a reasonable treatment option |
2019 Carl Lee [26] | Retrospective—cohort study | - Droperidol 0.625 mg IV used most of the time | 2b | - Droperidol IV to treat nausea and vomiting in CHS significantly reduced length of stay (6.7 vs. 13.9 h) compared to the no droperidol treatment group - Median time to discharge after final drug administration was also shorter (137 min vs 185 min) - Overall use of antiemetic was less in the droperidol group |
2017 Sorensen J[15]. | Retrospective—systematic review | - Abstinence | 3a | - Abstinence is the only definitive treatment identified for CHS |